It’s not something everyone wants to talk about. But we want to get the word out there. And that starts with doing the math.
Colon cancer is 90% preventable if detected early. In 2013, an estimated 23,900 new cases were diagnosed in Canada. More than 9,200 Canadians lost their lives that same year. Something does not add up! At Colon Cancer Canada we are working towards drastically changing these numbers. It is our wish that no one experiences the pain and suffering of colon cancer. It is preventable, treatable, and beatable!
If you would like to hear from us about our annual events, you can click here to subscribe to our mailing list!
Colon Cancer Canada does not offer medical advice or opinions or preferences for visitors to our website, nor do we provide medical referrals. We do not approve or endorse any particular treatment or service found through our website and/or links. If any visitor has medical questions or concerns, we urge him/her to contact his/her physician.
Participate in Survey on Stivarga for Treatment of Metastatic Colorectal Cancer!
Please take a few moments of your time to participate in our survey about regorafenib (Stivarga) for the treatment of patients with metastatic colorectal cancer and/or send it to friends, colleagues or fellow support group members.
The purpose of this survey is to provide Colon Cancer Canada and the Canadian Cancer Survivor Network (CCSN) with insights and perspectives about living with and managing metastatic colorectal cancer from patients and caregivers in order to complete a patient evidence submission for regorafenib (Stivarga) for the treatment of patients with metastatic colorectal cancer (CRC) who have been previously treated with fluoropyrimidine-based chemotherapy, oxaliplatin, irinotecan, an anti-VEGF therapy, and, if KRAS wild type, an anti-EGFR therapy; for patients with ECOG status of ≤ 1.
Go to https://www.surveymonkey.com/s/YXSQNMZ to access the survey.
This survey will be open until noon on October 27, 2014 to enable us to submit our patient evidence submission will be submitted to the pan-Canadian Oncology Drug Review on October 31, 2014.
Thank you for your participation!